MaxQ AI, the industry-leading healthcare technology company that delivers comprehensive clinical workflow with improved patient triage and diagnosis, announced today a multi-year partnership with FUJIFILM Medical Systems U.S.A., Inc., a leading provider of enterprise imaging solutions, to commercialize the ACCIPIO® Clinical Platform.

The Accipio Clinical Platform generates multiple insights into a patient’s medical imaging study that may provide a faster and clinically accurate diagnosis. The platform is comprised of Accipio Ix (Intracranial Hemorrhage (ICH) triage and notification, Accipio Ax (Slice-Level Annotation), and Accipio Dxg (Triage for ICH Presence or Absence)**. MaxQ is the only AI platform company offering advanced AI applications and AI platform solutions, such as MaxQ Xpress, as a seamless, integrated offering, secured through ISO 27001 and ISO 27799 cybersecurity standards. When launched through Fujifilm’s Synapse PACS platform, which ranks among the fastest and most secure enterprise imaging solutions in the industry—the Accipio and Synapse seamless solution deliver deep clinical and actionable insights, enabling clinicians to make faster assessments of patients.

“At MaxQ, our goal is to equip physicians with AI-based solutions that enable them to deliver faster, more confident patient care, while reducing costs, and physician workload,” says Michael Rosenberg, Chief Executive Officer of MaxQ. “We’ve worked extensively with Fujifilm over the last year on our deployment at Capital Health Hospitals in New Jersey. In collaboration with Fujifilm and the wonderful staff at Capital Health Hospital, our teams have successfully integrated Accipio into Fujifilm’s Synapse PACS, achieving a seamless clinical workflow enhanced with deep clinical AI.”

About Fujifilm
FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of innovative diagnostic imaging products and medical informatics solutions that meet and exceed the evolving needs of healthcare facilities today and into the future. It’s ever expanding medical imaging solutions span digital radiography (DR), detectors, portables and suites, mammography systems with digital breast tomosynthesis, computed tomography solutions for oncology and radiology applications, technologically advanced flexible and surgical endoscopy and fluoroscopy solutions. Fujifilm enables interoperability through its Systems Integration offering as well as its comprehensive, AI-supported Synapse® Enterprise Imaging portfolio, which includes the TeraMedica Division of Fujifilm. Fujifilm’s in vitro diagnostics (IVD) portfolio includes clinical lab reagents, and biomarkers to assess the risk for the development of hepatocellular carcinoma in patients with chronic liver disease. FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Lexington, Massachusetts. For more information please visit http://www.fujifilmhealthcare.com.

Health IT Homepage